There are five muscarinic receptors implicated in a range of neurological diseases. The M1 and M4 muscarinic receptors are particularly attractive targets for treating conditions including ...

Researchers from Maplight Therapeutics Inc. presented preclinical data for the investigational muscarinic M1/M4 receptor agonist ML-007, being evaluated for the treatment of neuropsychiatric disorders ...

The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

It is administered as a twice-daily oral medication that works by interacting with muscarinic acetylcholine receptors (mAChR) (M1, M2, M3, and M4) in the brain. Xanomeline acts as a mAChR agonist ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator ... KarXT combines xanomeline, a novel muscarinic M1/M4 agonist, with trospium, an already-approved muscarinic ...

The M1/M4 muscarinic receptor agonist is vying to be the first drug to reach the market for schizophrenia with a new mechanism of action in decades. It is also in phase 3 clinical testing as an ...

Background: Many neuromuscular blockers act as negative allosteric modulators of muscarinic acetylcholine receptors by decreasing affinity and potency of acetylcholine. The neuromuscular blocker ...